694529-38-9

Usage

Uses

Used in Pharmaceutical Industry:
(R)-[1-(4-nitrophenyl)ethyl]carbamic acid t-butyl ester is used as a reagent for the synthesis of various pharmaceutical compounds. Its chiral nature plays a vital role in the development of enantiomerically pure drugs, which can have different biological activities and reduce potential side effects.
Used in Agrochemical Industry:
In the agrochemical industry, (R)-[1-(4-nitrophenyl)ethyl]carbamic acid t-butyl ester is employed as a reagent in the production of chiral pesticides and other agrochemicals. Its use contributes to the development of more effective and environmentally friendly products.
Used in Asymmetric Synthesis Research:
(R)-[1-(4-nitrophenyl)ethyl]carbamic acid t-butyl ester is used as a significant molecule in the study of asymmetric synthesis. This research area focuses on the development of methods to produce chiral compounds with a specific arrangement of atoms, which is essential for creating enantiomerically pure compounds with desired biological activities.
Used in Chiral Resolution Techniques:
This chemical compound is also utilized in the study and development of chiral resolution techniques. These techniques aim to separate enantiomers, which can have different effects on biological systems, allowing for the production of more effective and safer drugs and chemicals.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 57233-86-0 d-(+)-α-methyl-4-nitrobenzylamine hydrochloride 

Downstream Products

• 694529-17-4 N-(4-t-butylbenzyl)-N'-[(1R)-1-(4-aminophenyl)ethyl]thiourea 
• 910534-76-8 (R)-[1-(4-methanesulfonylaminophenyl)ethyl]carbamic acid t-butyl ester 
• 694529-76-5 (S)-4-methanesulfonamido-α-methylbenzylamine 
• 694529-72-1 [1-(4-acetylamino-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 177948-74-2 (R)-N-[4-(1-aminoethyl)phenyl]acetamide 
• 65645-32-1 4-((R)-1-Amino-ethyl)-phenylamine 
• 262368-44-5 (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The present invention

Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists

A series of chain-branched 1,3-dibenzylthiourea derivatives were synthesized, and tested their antagonist activity against vanilloid receptor 1. Chain-branching led to a significant change in the mode of action and the potency. (R)-Methyl or ethyl-branched 1,3-dibenzylthiourea derivatives showed the most potent antagonist activity up to the IC50 value of 0.05 μM which is 10-fold more potent than capsazepine.